Study of the Proteome and Cytokines During Inflammatory Syndromes of Different Etiologies.

Status

Terminated

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01903642

Acronym

Proteome

Enrollment

Registered

2013-07-19

Start date

2010-03-31

Completion date

2012-02-29

Last updated

2013-07-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory Disease

Brief summary

The hypotheses of our research are based on the fact that various pathological states, infection, cancer, inflammatory disease, can induce an inflammatory syndrome, through different pathways, even though the clinical presentation can be identical. The identification of biological markers specific to an etiology would therefore allow a faster diagnosis and improve care for patients. We thus took an interest in the three groups of diseases most frequently responsible for an inflammatory syndrome, infections, cancers and auto-immune diseases. To achieve this, various methods will be used.

Interventions

OTHERproteomic analysis

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Inclusion criteria

Patients presenting an inflammatory syndrome, defined by elevated C-reactive protein (CRP\>50mg/L), whose etiology is related to infection, cancer or an inflammatory disease. * Patients not on treatment (corticoids, immunosuppressive drugs) during the 7 days preceding inclusion * Age: 18-90 years * Patients covered by the National Health Insurance Agency * signed written informed consent form

Exclusion criteria

* \- Any patient not meeting the inclusion criteria * Pregnant patients

Design outcomes

Primary

Measure	Time frame
determination of usual parameters of inflammation	at baseline

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026